Dr. Chase on the Standard of Care for Uterine Leiomyosarcoma

Dana Chase, MD
Published: Wednesday, May 09, 2018



Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.

If disease is recurrent or advanced upon presentation, it is standard to give systemic treatment, says Chase. The standard treatment for those patients include chemotherapy. There are currently several FDA-approved options that can be used in that setting, per the guidelines.

Traditionally, gynecologic oncologists used docetaxel and gemcitabine. That has really been the go-to regimen for these tumors, says Chase. Recent data suggests that single-agent doxorubicin or doxorubicin with olaratumab (Lartruvo) are good alternatives. Chase states that doxorubicin with olaratumab could potentially be superior to docetaxel and gemcitabine, though physicians do not have data on that yet. These data are expected within the next year or 2, says Chase.
 


Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.

If disease is recurrent or advanced upon presentation, it is standard to give systemic treatment, says Chase. The standard treatment for those patients include chemotherapy. There are currently several FDA-approved options that can be used in that setting, per the guidelines.

Traditionally, gynecologic oncologists used docetaxel and gemcitabine. That has really been the go-to regimen for these tumors, says Chase. Recent data suggests that single-agent doxorubicin or doxorubicin with olaratumab (Lartruvo) are good alternatives. Chase states that doxorubicin with olaratumab could potentially be superior to docetaxel and gemcitabine, though physicians do not have data on that yet. These data are expected within the next year or 2, says Chase.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x